Keyword: EuroBiotech Report
In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million.
In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.
The U.K. is currently a leading European location for clinical trials but that position could be threatened by Brexit and other factors.
The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.
The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.
The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.
In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.
In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.
The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.
AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.